Literature DB >> 12412814

When should densitometry be repeated in healthy peri- and postmenopausal women: the Danish osteoporosis prevention study.

B Abrahamsen1, N Nissen, A P Hermann, B Hansen, O Bärenholdt, P Vestergaard, C L Tofteng, S Pors Nielsen.   

Abstract

Intervention should be considered in postmenopausal women with bone mineral density (BMD) > or = 1 SD below the reference (T or Z score < -1). However, it is unclear when densitometry should be repeated. This study aimed at determining the need for repeat DXA within 5 years in untreated peri-/postmenopausal women to detect declines of T or Z score to below -1 with 85% confidence. A cohort of 925 healthy women (aged 51.2 +/- 2.9 years) were followed within the Danish Osteoporosis Prevention Study (DOPS) for 5 years without hormone-replacement therapy (HRT). DXA of spine, hip, and forearm was done at 0,1, 2, 3, and 5 years (Hologic QDR-1000/2000). The annual loss in SD units was 0.12 +/- 0.10 at the spine (1.3%), 0.10 +/- 0.09 at the femoral neck (1.2%), and 0.07 +/- 0.09 at the ultradistal (UD) forearm (1.0%). Accordingly, T scores below -1 developed earlier at the spine. The need for a future DXA scan to predict declines of T and Z scores below -1 depended strongly on baseline BMD. In subjects with a positive T score, the risk of developing T < -1 remained at <15% for 5 years at all measured sites. A new scan was needed after 1 year if the T score was below -0.5, and after 3 years if the T score was between 0 and -0.5. Slightly longer intervals apply if Z scores are used. Follow-up densitometry in untreated women should be individually targeted from baseline BMD rather than scheduled at fixed time intervals. An algorithm for planning repeat densitometry in perimenopausal women is provided.

Entities:  

Mesh:

Year:  2002        PMID: 12412814     DOI: 10.1359/jbmr.2002.17.11.2061

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Timing of follow-up densitometry in hormone replacement therapy users for optimal osteoporosis prevention.

Authors:  Miguel A Checa; L Del Rio; J Rosales; X Nogués; J Vila; R Carreras
Journal:  Osteoporos Int       Date:  2004-12-23       Impact factor: 4.507

2.  Correlation of transmenopausal bone mass in healthy white women: a long-term longitudinal study.

Authors:  L-J Zhao; P-Y Liu; R Recker; H-W Deng
Journal:  Osteoporos Int       Date:  2006-07-29       Impact factor: 4.507

3.  Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment.

Authors:  T-I Chiang; I-C Chang; H-S Lee; H Lee; C-H Huang; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-08-24       Impact factor: 4.507

4.  Increased serum osteopontin is a risk factor for osteoporosis in menopausal women.

Authors:  I-C Chang; T-I Chiang; K-T Yeh; H Lee; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-03-18       Impact factor: 4.507

5.  Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans.

Authors:  H-J Lee; S-Y Kim; G S Kim; J-Y Hwang; Y-J Kim; B Jeong; T-H Kim; E K Park; S H Lee; H-L Kim; J-M Koh; J-Y Lee
Journal:  Osteoporos Int       Date:  2009-11-28       Impact factor: 4.507

6.  Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents.

Authors:  Claudie Berger; Lisa Langsetmo; Lawrence Joseph; David A Hanley; K Shawn Davison; Robert Josse; Nancy Kreiger; Alan Tenenhouse; David Goltzman
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

7.  Poor sleep quality and later sleep timing are risk factors for osteopenia and sarcopenia in middle-aged men and women: The NEO study.

Authors:  Eliane A Lucassen; Renée de Mutsert; Saskia le Cessie; Natasha M Appelman-Dijkstra; Frits R Rosendaal; Diana van Heemst; Martin den Heijer; Nienke R Biermasz
Journal:  PLoS One       Date:  2017-05-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.